Q3 2025 WAVE Life Sciences Ltd Earnings Call Transcript

Nov 10, 2025 / 01:30 PM GMT

Release Date Price: €6.7 (+0.75%)

Transcript 10-Q8-K

Key Points

Positve

WAVE Life Sciences Ltd (WVE) demonstrated significant and durable human activity reductions with a single dose of WVE007, showing potential for meaningful weight loss and prevention of rebound weight gain.
The company is advancing its pipeline with innovative RNA editing and siRNA technologies, including a new RNA editing clinical candidate, WVE 008, for liver disease.
WVE007 has shown promising results in clinical trials, with significant dose-dependent activity reductions and sustained effects, supporting the potential for once or twice yearly dosing.
WVE 006 has achieved key treatment goals in RNA editing for AATD, showing potential to restore physiological AAT production and offering a paradigm shift from weekly IV therapies.
The company has a strong financial position with $196.2 million in cash and cash equivalents, extending its expected cash runway into Q2 2027 with additional ATM proceeds and GSK milestones.

Negative

Research and development expenses increased to $45.9 million, driven by advancing programs and compensation-related expenses, contributing to a net loss of $53.9 million for the quarter.
The company faces risks and uncertainties related to forward-looking statements, which could cause actual results to differ materially from expectations.
There is ongoing concern about the potential for off-target effects and bystander edits in RNA editing programs, which could impact the safety and efficacy of treatments.
The competitive landscape in the obesity market presents pricing pressures, which may affect the commercial viability of WVE's treatments.
The company is still in the early stages of clinical trials for several programs, and there is significant clinical de-risking required before potential market approval.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

WVE.OQ - WAVE Life Sciences Ltd
Q3 2025 WAVE Life Sciences Ltd Earnings Call
Nov 10, 2025 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Life Sciences. Third, we ask that you please hold all questions until the completion of the formal remarks, at which time you'll be given instructions for the question-and-answer session. Also, as a reminder, this conference is being recorded today. I will now turn the call over to Kate Rausch, Vice President of Corporate Affairs and Investor Relations.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you operator, and good morning to everyone on the call. Earlier this morning we issued a press release outlining our 3rd quarter 2025 earnings update. Joining me today with

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.